2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2020
High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers
Yoon EC, Wilson P, Zuo T, Pinto M, Cole K, Harigopal M. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Human Pathology 2020, 102: 13-22. PMID: 32565323, DOI: 10.1016/j.humpath.2020.06.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNon-TNBC casesFrequency of p16TNBC casesAndrogen receptorBreast cancerTissue microarrayAggressive clinical courseAndrogen receptor expressionInvasive ductal carcinomaHistologic grade 3Basal-like breast cancer subtypeNovel prognostic markerBreast cancer subtypesExpression of p16Clinical courseCytokeratin 5/6Ductal carcinomaPrognostic markerReceptor expressionRoutine biomarkersSignificant statistical differenceClinical dataGrade 3Cancer subtypes